Polar Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Polar Capital’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100,000	Closed	-$3.61M	–	296
2018 Q4	$3.61M	Sell	100,000 -25,000	-20%	-$1.17M	0.04%	222
2018 Q3	$7.69M	Buy	125,000 +50,000	+67%	+$3.21M	0.07%	195
2018 Q2	$5.07K	Buy	75,000 +45,000	+150%	+$2.52M	0.03%	222
2018 Q1	$1.63M	Sell	30,000 -70,000	-70%	-$3.92M	0.02%	247
2017 Q4	$5.97M	Buy	+100,000	New	+$6.06M	0.06%	193
2015 Q3	–	Sell	-36,130	Closed	-$638K	–	298
2015 Q2	$638K	Buy	36,130 +14,820	+70%	+$272K	0.01%	262
2015 Q1	$668K	Sell	21,310 -4,097	-16%	-$119K	0.01%	261
2014 Q4	$742K	Buy	25,407 +8,794	+53%	+$223K	0.01%	246
2014 Q3	$344K	Buy	+16,613	New	+$328K	0.01%	255

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Polar Capital's AERI Position: Q1 2019 in Review

Polar Capital sold out of Aerie Pharmaceuticals (AERI) in Q1 2019, closing a stake of 100,000 shares — an estimated $3.61M sold.

Polar Capital first reported a position in AERI in Q3 2014 and held it in 9 quarters. The position peaked at $7.69M in Q3 2018. 176 funds tracked by Wall St. Rank hold AERI as of Q1 2019.

Polar Capital reported no remaining Aerie Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Polar Capital sold 100,000 Aerie Pharmaceuticals shares in Q1 2019, an estimated $3.61M.
Polar Capital first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 9 quarters.
Polar Capital's Aerie Pharmaceuticals position peaked at $7.69M in Q3 2018.
176 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2019.

Based on Polar Capital's 13F filing for Q1 2019, filed 15 May 2019.